Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN-1 nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis
2026-525877-38-00Phase 3Authorised
- Sponsor
- Trevi Therapeutics
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in chronic cough comparing Nalbuphine ER with Placebo to match nalbuphine ER (2 arms). Primary endpoint: Relative change from baseline in 24-hour cough frequency at Week 26. Planned start Oct 2026; status: authorised.
02
Drugs
nalbuphine
03
Conditions
chronic cough
Beyond the preview
Go deeper on 2026-525877-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525877-38-00.